WallStSmart

Inogen Inc (INGN)vsStryker Corporation (SYK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Stryker Corporation generates 7089% more annual revenue ($25.27B vs $351.50M). SYK leads profitability with a 13.2% profit margin vs -7.1%. SYK appears more attractively valued with a PEG of 1.43. SYK earns a higher WallStSmart Score of 59/100 (C).

INGN

Hold

49

out of 100

Grade: D+

Growth: 5.3Profit: 2.0Value: 5.7Quality: 8.0
Piotroski: 5/9Altman Z: 1.71

SYK

Buy

59

out of 100

Grade: C

Growth: 6.0Profit: 6.5Value: 4.0Quality: 6.5
Piotroski: 3/9Altman Z: 2.18
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

INGNUndervalued (+88.9%)

Margin of Safety

+88.9%

Fair Value

$55.16

Current Price

$5.98

$49.18 discount

UndervaluedFair: $55.16Overvalued
SYKSignificantly Overvalued (-35.2%)

Margin of Safety

-35.2%

Fair Value

$223.02

Current Price

$305.66

$82.64 premium

UndervaluedFair: $223.02Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

INGN3 strengths · Avg: 10.0/10
Price/BookValuation
0.9x10/10

Reasonable price relative to book value

EPS GrowthGrowth
87.3%10/10

Earnings expanding 87.3% YoY

Debt/EquityHealth
0.0910/10

Conservative balance sheet, low leverage

SYK1 strengths · Avg: 9.0/10
Market CapQuality
$112.44B9/10

Large-cap with strong market position

Areas to Watch

INGN4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
3.4%4/10

3.4% revenue growth

Altman Z-ScoreHealth
1.714/10

Distress zone — elevated risk

Market CapQuality
$173.55M3/10

Smaller company, higher risk/reward

PEG RatioValuation
3.482/10

Expensive relative to growth rate

SYK3 concerns · Avg: 3.7/10
P/E RatioValuation
33.9x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
2.6%4/10

2.6% revenue growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : INGN

The strongest argument for INGN centers on Price/Book, EPS Growth, Debt/Equity.

Bull Case : SYK

The strongest argument for SYK centers on Market Cap. PEG of 1.43 suggests the stock is reasonably priced for its growth.

Bear Case : INGN

The primary concerns for INGN are Revenue Growth, Altman Z-Score, Market Cap.

Bear Case : SYK

The primary concerns for SYK are P/E Ratio, Revenue Growth, Piotroski F-Score.

Key Dynamics to Monitor

INGN profiles as a turnaround stock while SYK is a value play — different risk/reward profiles.

INGN carries more volatility with a beta of 1.59 — expect wider price swings.

INGN is growing revenue faster at 3.4% — sustainability is the question.

SYK generates stronger free cash flow (415M), providing more financial flexibility.

Bottom Line

SYK scores higher overall (59/100 vs 49/100). INGN offers better value entry with a 88.9% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Inogen Inc

HEALTHCARE · MEDICAL DEVICES · USA

Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other physicians, and third-party payers in the United States and internationally. The company is headquartered in Goleta, California.

Visit Website →

Stryker Corporation

HEALTHCARE · MEDICAL DEVICES · USA

Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.

Visit Website →

Want to dig deeper into these stocks?